<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C1C5ABD2-33BD-46CB-886D-987A1BE45436"><gtr:id>C1C5ABD2-33BD-46CB-886D-987A1BE45436</gtr:id><gtr:firstName>Amit</gtr:firstName><gtr:otherNames>Chunilal</gtr:otherNames><gtr:surname>Nathwani</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FB644B47-320F-46E7-BCB9-449448CB6F9A"><gtr:id>FB644B47-320F-46E7-BCB9-449448CB6F9A</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Davidoff</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1C74F08A-DACF-4A6D-8B8C-87B2D60CDB7F"><gtr:id>1C74F08A-DACF-4A6D-8B8C-87B2D60CDB7F</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:otherNames>G</gtr:otherNames><gtr:surname>Tuddenham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C57B635D-F825-4AA3-B68D-BD6AC10FF6ED"><gtr:id>C57B635D-F825-4AA3-B68D-BD6AC10FF6ED</gtr:id><gtr:firstName>Olivier</gtr:firstName><gtr:surname>Danos</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0902219"><gtr:id>3693F6E1-DC1F-4976-AEEF-0DCFB6B7A8A5</gtr:id><gtr:title>Preclinical evaluation of rAAV encoding a novel highly expressed Factor VIII molecule for haemophilia A gene therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0902219</gtr:grantReference><gtr:abstractText>In the proposed study we wish to test a new approach called gene therapy for the treatment of patients with haemophilia A. This inherited disorder in which life threatening bleeding occurs without trauma results from an absence or defect of a blood clotting protein called Factor FVIII (FVIII) that arises due to mutations in the FVIIIX gene. The goal of our gene therapy approach, therefore, is to treat the disease by transferring to the patient?s liver, a normal copy of the FVIII gene so that normal FVIII protein can be continuously produced by the patient?s own cells. To this end we have developed a novel vector based on adeno-associated virus (rAAV8-HLP-codop-hFVIII) which is highly efficient at transferring the normal FVIII gene to the liver, its natural site of synthesis. Importantly, AAV has the best safety profile among gene transfer vectors of viral origin. In murine models we have consistently achieved long-term expression of human FVIII at levels that would be sufficient to prevent spontaneous life threatening bleeding in haemophilia A patients following a single injection of rAAV8-HLP-codop-hFVIII. Prior to evaluating this new vector in patients with haemophilia A, we have to establish its safety and efficacy to the rigorous standards required by the regulators using high quality clinical grade vector as opposed to research grade vector. This application is therefore designed to generate sufficient quantities of clinical grade rAAV8-HLP-codop-hFVIII vector and then carefully and critically evaluate its safety and efficacy in a context relevant to humans. The results of this study will be used to support the initiation of a clinical trial in patients with severe haemophilia A. Success with our approach could significantly impact on a wide variety of life threatening genetic disorders including alpha-1 antitrypsin deficiency, lysosomal storage and urea cycle disorders.</gtr:abstractText><gtr:technicalSummary>The goal of this proposal is to generate sufficient data to support a Phase I/II gene therapy trial for haemophilia A (HA), the most common inherited bleeding disorder that results from mutations in the human factor VIII (hFVIII) gene. We have already developed a new gene therapy approach for a related bleeding disorder, haemophilia B, with a recombinant adeno-associated virus (rAAV) vector, which is currently being evaluated in a clinical trial. This experience will be used to facilitate the clinical transition of a novel, more potent human factor VIII (codop-hFVIII) molecule that overcomes the poor expression of the wild type FVIII gene. A single administration of a rAAV vector encoding codop-FVIII leads to supraphysiological FVIII levels without toxicity in mice. This level of expression is at least 400-fold greater than required for therapeutic efficacy (0.05IU/ml). Further evaluation of this promising approach is now being proposed in a context relevant to humans.</gtr:technicalSummary><gtr:fund><gtr:end>2015-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1085010</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Jude Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Surgery</gtr:department><gtr:description>St Jude Children's Research Hospital</gtr:description><gtr:id>1C5CC244-5A38-4E15-AAF2-68A11DF9077F</gtr:id><gtr:impact>Several papers listed in the publication record
Commencement of a Phase I/II clinical trial</gtr:impact><gtr:partnerContribution>Made clinical grade vector for use in the clinical trial for both haemophilia A and B</gtr:partnerContribution><gtr:piContribution>1. Establishment of scale-up of vector production for both FIX and FVIII
2. Development of preclinical data for regulatory approval in UK and USA for both haemophilia A and B
3. Commencement and recruitment of patients to the Phase I/II clinical trial
4. Evaluation of gene transfer efficiency in patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Molecular and Tissue Engineering</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:fundingRef>RP-PG-0310-1001</gtr:fundingRef><gtr:id>871E2BDA-9201-4ABB-B9A7-13E8FEC0D95E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4932198D-7465-43E2-B3A8-49EE1756913E"><gtr:id>4932198D-7465-43E2-B3A8-49EE1756913E</gtr:id><gtr:title>Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vector.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Methods &amp; clinical development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f788313650c7e804f72bd5761e35e363"><gtr:id>f788313650c7e804f72bd5761e35e363</gtr:id><gtr:otherNames>Piras BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2329-0501</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C92FAF69-C18F-41B0-8FA6-A7DB04CAF56B"><gtr:id>C92FAF69-C18F-41B0-8FA6-A7DB04CAF56B</gtr:id><gtr:title>Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50674a46ba09c7a155f6b51d43ff8be5"><gtr:id>50674a46ba09c7a155f6b51d43ff8be5</gtr:id><gtr:otherNames>McIntosh J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAA73579-206D-4F5D-A6D5-7EADA245E324"><gtr:id>CAA73579-206D-4F5D-A6D5-7EADA245E324</gtr:id><gtr:title>Current status of haemophilia gene therapy.</gtr:title><gtr:parentPublicationTitle>Haemophilia : the official journal of the World Federation of Hemophilia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21e0ddeff5e71f6858b80015b35dbfd6"><gtr:id>21e0ddeff5e71f6858b80015b35dbfd6</gtr:id><gtr:otherNames>High KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1351-8216</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/046A0A4B-017C-4572-B787-625BFB59BA5C"><gtr:id>046A0A4B-017C-4572-B787-625BFB59BA5C</gtr:id><gtr:title>Progress towards gene therapy for haemophilia B.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb7e5c339c1607f10a4d6e1d2f0b85b6"><gtr:id>bb7e5c339c1607f10a4d6e1d2f0b85b6</gtr:id><gtr:otherNames>Patel N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C52C9D5-24D6-4EAD-A332-A45D3769959F"><gtr:id>7C52C9D5-24D6-4EAD-A332-A45D3769959F</gtr:id><gtr:title>Genetic Targeting of the Albumin Locus to Treat Hemophilia.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a2a1d62dba372f871437f679c0aec714"><gtr:id>a2a1d62dba372f871437f679c0aec714</gtr:id><gtr:otherNames>Davidoff AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/142B1987-E956-43B5-B52C-A35719A592A0"><gtr:id>142B1987-E956-43B5-B52C-A35719A592A0</gtr:id><gtr:title>New and improved AAVenues: current status of hemophilia B gene therapy.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44c4b935756d37ca85a3b8488d63ef26"><gtr:id>44c4b935756d37ca85a3b8488d63ef26</gtr:id><gtr:otherNames>Brimble MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/809976DE-0193-4F63-9771-BC0ED36CDB6A"><gtr:id>809976DE-0193-4F63-9771-BC0ED36CDB6A</gtr:id><gtr:title>Vector systems for prenatal gene therapy: principles of adeno-associated virus vector design and production.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24fab71c9a756c69f4a31b47560e277c"><gtr:id>24fab71c9a756c69f4a31b47560e277c</gtr:id><gtr:otherNames>Binny CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43101666-14C8-46A7-8C76-DC8D44617199"><gtr:id>43101666-14C8-46A7-8C76-DC8D44617199</gtr:id><gtr:title>Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c745e5f96e2db4ca9a165bd1a95a4858"><gtr:id>c745e5f96e2db4ca9a165bd1a95a4858</gtr:id><gtr:otherNames>Tremblay JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0BCBE3E5-E17B-4CBD-B731-7AFCBC7C22DB"><gtr:id>0BCBE3E5-E17B-4CBD-B731-7AFCBC7C22DB</gtr:id><gtr:title>Codon optimization of human factor VIII cDNAs leads to high-level expression.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/82955e7b716423d04ec914f4d1d3c910"><gtr:id>82955e7b716423d04ec914f4d1d3c910</gtr:id><gtr:otherNames>Ward NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3510971A-1770-4AEF-A7CF-2ED0F1FFC496"><gtr:id>3510971A-1770-4AEF-A7CF-2ED0F1FFC496</gtr:id><gtr:title>Our journey to successful gene therapy for hemophilia B.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f0aa3df1963a7045e867bf82306d36f1"><gtr:id>f0aa3df1963a7045e867bf82306d36f1</gtr:id><gtr:otherNames>Nathwani AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/71E7DF7F-4239-42B4-B701-7062F0042F0E"><gtr:id>71E7DF7F-4239-42B4-B701-7062F0042F0E</gtr:id><gtr:title>Haemophilia gene therapy: Progress and challenges.</gtr:title><gtr:parentPublicationTitle>Blood reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/859726ce1d96ef2f459237046cc629f9"><gtr:id>859726ce1d96ef2f459237046cc629f9</gtr:id><gtr:otherNames>Lheriteau E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0268-960X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6395570F-B49F-457C-A0D5-47CE53BD64C6"><gtr:id>6395570F-B49F-457C-A0D5-47CE53BD64C6</gtr:id><gtr:title>Gene Therapy for Hemophilia.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c4a274803dd01b11758a73553d1e907"><gtr:id>1c4a274803dd01b11758a73553d1e907</gtr:id><gtr:otherNames>Nienhuis AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902219</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>